Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor Authors: Yujun Lin, Di Wu, Lujing Jiang, Qin Shi Published: 2026 ABSTRACT BackgroundThoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rare and highly aggressive malignancy with poor prognosis and no established standard therapy. This study aimed to map the research landscape of SMARCA4-UT through bibliometric analysis to guide clinical decision-making and research prioritization.MethodsPublications on thoracic SMARCA4-UT were retrieved from the Web of Science Core Collection and Scopus from 2000 to 2025. After screening, 132 articles and reviews were included. Bibliometrix and CiteSpace were used to analyze publication trends, geographic and institutional distribution, author productivity, collaboration networks, keyword evolution, thematic structure, and highly cited articles.ResultsSMARCA4-UT research expanded rapidly, with 31.95% annual growth rate and 32.25 average citations per article, reflecting rising academic impact. China (28.8%) and Japan (23.5%) led global output, forming a China–US dual-core collaboration network. Mechanistic studies on the SWI/SNF complex and BRG1 are mature, while clinical and therapeutic research remains underdeveloped. Temporal analysis revealed a shift toward diagnostic standardization after the 2021 WHO classification.ConclusionsSMARCA4-UT research is in a rapid growth phase, with a substantial gap between mechanistic advances and clinical translation. Immunochemotherapy is the current first-line backbone, while targeted and combinatorial strategies remain exploratory. These findings provide evidence-based guidance for clinical practice and research design, highlighting the urgent need for biomarker-driven therapy and large-scale international collaboration to improve patient outcomes.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s12672-026-05504-0. Introduction SMARCA4 (BRG1), a core component of the SWItch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex, functions as a critical tumor suppressor through pRb-mediated cell cycle regulation [1–3]. Its dysregulation occurs across diverse human cancers [4], but the recognition of thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) as a distinct clinicopathological entity is recent. First described in 2015 as “SMARCA4-deficient thoracic sarcomas” [5–7]. Subsequent research by Rekhtman et al. reclassified these as smoking-associated undifferentiated carcinomas, leading to formal designation in the 2021 WHO Classification [8–12]. SMARCA4-UT presents significant clinical challenges, predominantly affecting middle-aged male heavy smokers with large, aggressive intrathoracic masses and dismal median survival of 4–7 months [5, 7]. Diagnosis relies on combined undifferentiated morphology and BRG1 loss by immunohistochemistry (IHC) [13–18]. Morphological assessment serves as the foundational step, revealing a dedifferentiated or undifferentiated cellular phenotype that lacks typical epithelial architecture, such as glandular or squamous differentiation. Histologically, these tumors present as diffuse sheets of large, undifferentiated cells—frequently exhibiting rhabdoid morphology—and demonstrate weak or absent keratin expression [5–7]. IHC is crucial for definitive diagnosis, which is established by the characteristic loss of BRG1 protein expression. The frequent co-loss of BRM (SMARCA2) serves as a valuable diagnostic clue. Supporting IHC findings may include expression of stem cell markers (e.g., CD34, SOX2, SALL4), while epithelial markers such as claudin-4 are typically negative or only focally positive [19]. Finally, molecular profiling shows truncating SMARCA4 mutations providing genetic evidence to support the diagnosis and rule out other entities. Various molecular techniques, including Sanger sequencing (Sanger-seq) [5, 20], fluorescence in situ hybridization (FISH) [8], and next-generation sequencing (NGS), encompassing both RNA sequencing (RNA-seq) [5, 21] and targeted NGS [7], have been utilized to diagnose SMARCA4-UT and characterize its genetic alterations. Each method has significant limitations; FISH detects only 35% of alterations due to prevalent copy-neutral loss of heterozygosity, while NGS can miss 12.5% of cases, and IHC sometimes shows reduced rather than negative expression [8]. Therefore, a combination of NGS and IHC is recommended for accurate diagnosis to overcome the individual shortcomings of each technique. This composite diagnostic profile is essential for differentiating SMARCA4-UT from SMARCA4-deficient non-small cell lung carcinoma (NSCLC), which typically manifests as conventional adenocarcinoma or squamous cell carcinoma with retained epithelial features [22]. Therapeutic management remains problematic with no established standard of care. The tumor is characterized by aggressive biological behavior [5–8], with most patients presenting at advanced stages and a poor prognosis [11, 23]. Even patients who undergo surgery have a high recurrence risk; therefore, surgical intervention may be considered primarily for Stage I patients [24]. Beyond surgery, SMARCA4-UT demonstrates marked resistance to conventional chemotherapy and radiotherapy [25–27]. ICI efficacy in SMARCA4-UT is highly variable. Exceptional responses occur in some patients, but many derive no benefit due to an immune-desert tumor microenvironment lacking T-cell infiltration [11, 28–33]. Response variability is influenced by biomarker interplay: high TMB may predict benefit, while STK11/KEAP1 co-mutations are associated with primary resistance [33]. This therapeutic void has spurred extensive preclinical efforts to identify synthetic lethal vulnerabilities. Promising strategies include targeting epigenetic regulators, such as Enhancer of Zeste Homolog 2 (EZH2) inhibitors [34, 35] and Bromodomain and Extra-Terminal domain protein (BET) inhibitors [36]; exploiting cell cycle and DNA damage vulnerabilities with Cyclin-Dependent Kinase 4/6 (CDK4/6) inhibitors [37, 38], Ataxia Telangiectasia and Rad3-related protein kinase (ATR) inhibitors [39, 40], and Poly(ADP-ribose) Polymerase (PARP) inhibitors [41]; and targeting metabolic dependencies such as Oxidative Phosphorylation (OXPHOS) inhibition [42, 43]. Aurora Kinase A (AURKA) inhibitors [44], KRASG12C inhibitors [8, 30] and immune microenvironment regulators ZG16B [45] also represent active areas of investigation.” However, these strategies are predominantly in the preclinical or early clinical trial phase, and no robust clinical guidelines currently exist [46]. SMARCA4-UT research remains fragmented, constrained by small sample sizes and retrospective designs. Critical knowledge gaps persist in molecular heterogeneity, immunotherapy response determinants, and therapy resistance mechanisms [47]. The tumor’s recent 2021 WHO classification underscores unmet needs: absence of dedicated clinical trials, predictive biomarkers, and standardized diagnostic criteria. Translating preclinical vulnerabilities—targeting CDK4/6, EZH2, or ATR pathways—into clinical applications remains largely unexplored. Recent reviews [19, 22, 46, 48–51] emphasized that SMARCA4-UT represents a paradigm of epigenetically driven malignancies with immune-metabolic interdependence, yet quantitative mapping of global research dynamics remains absent. Bibliometric analysis provides a robust quantitative framework for evaluating research trends [52, 53]. widely applied across medical fields including oncology [54], inflammation [55], autoimmune disease [56], genetic disease [57]. This study of SMARCA4-UT aims to: (1) quantify research output growth and impact; (2) identify leading contributors and institutions; (3) visualize collaboration networks; (4) map thematic evolution and emerging hotspots; and (5) provide a comprehensive field overview. Our findings offer strategic insights to guide future research directions and accelerate progress against this aggressive malignancy. Materials and methods Data source and search strategy A comprehensive literature search was performed in the Web of Science Core Collection (WoSCC) and Scopus. The search period was restricted to publications indexed between January 1, 2000, and December 30, 2025. To improve disease specificity, the search strategy prioritized terms directly related to thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT), while retaining broader supplementary terms to capture earlier or inconsistently indexed publications. The WoSCC search strategy was as follows: TS = (“SMARCA4-deficient undifferentiated tumor” OR “SMARCA4 deficient undifferentiated tumor” OR “SMARCA4-UT” OR ((“SMARCA4” OR “BRG1”) AND (“undifferentiated tumor” OR sarcoma OR sarcomatoid) AND (thoracic OR lung OR pulmonary))). The Scopus search strategy was: TITLE-ABS-KEY (“SMARCA4-deficient undifferentiated tumor” OR “SMARCA4 deficient undifferentiated tumor” OR “SMARCA4-UT” OR ((“SMARCA4” OR “BRG1”) AND (“undifferentiated tumor” OR sarcoma OR sarcomatoid) AND (thoracic OR lung OR pulmonary))). The searches identified 205 records in WoSCC and 252 records in Scopus. After restricting the results to English-language articles and reviews, 160 WoSCC records and 215 Scopus records were retained. These records were imported into Zotero for merging and deduplication, yielding 246 unique records after removal of 129 duplicates. Manual screening was then performed by two independent investigators using predefined inclusion and exclusion criteria, with disagreements resolved by discussion or consultation with a third investigator. Studies were included if they primarily focused on thoracic SMARCA4-UT, including its clinicopathological characteristics, molecular features, diagnosis, prognosis, treatment, or related mechanisms. Studies limited to SMARCA4-mutant NSCLC, SCLC, other non-SMARCA4-UT malignancies, or general SWI/SNF/BRG1 biology without direct relevance to thoracic SMARCA4-UT were excluded. Finally, 132 eligible English-language publications were included in the bibliometric analysis, comprising 129 records indexed in WoSCC and 3 additional records retrieved from Scopus (Fig. 1). Data extraction and analysis All eligible records were exported in plain text format from WOSCC and Scopus for bibliometric analysis. The bibliometrix R package (version 4.1.3) was employed to analyze research landscape evolution, annual publication trends, author productivity, and strategic theme mapping. CiteSpace (version 6.1.R6) was utilized for constructing collaboration networks, timeline visualizations, keyword burst detection, and interdisciplinary knowledge flow analysis. Geographic distribution mapping was performed using R language with specialized geospatial coding. Graphpad Pism 9.0 provided data organization and supplementary visualization support. The literature screening flowchart was created using Microsoft PowerPoint. Descriptive statistics summarized publication outputs, citation patterns, and authorship metrics. Keyword co-occurrence and thematic evolution analyses identified emerging research trends. All analyses underwent rigorous quality control, including removal of duplicate records and manual validation to ensure accuracy. Fig. 1Flowchart of the study Flowchart of the study Results Main information of thoracic SMARCA4-UT research A total of 132 publications on thoracic SMARCA4-UT published between 2015 and 2025 were identified across 78 sources, with an annual growth rate of 31.95%, indicating rapidly increasing research interest. These studies involved 845 authors, with an average of 7.23 co-authors per document and only 5 single-authored papers, reflecting a highly collaborative research pattern; international co-authorship accounted for 7.576%. The publications cited 2,106 references, with a mean document age of 3.19 years and an average of 32.25 citations per document, suggesting notable academic impact. In total, 281 authors’ keywords were identified, highlighting the diversity of research themes in this field. Distribution by publication year Figure 2 shows the temporal trend of thoracic SMARCA4-UT research. Annual publications rose from 2 in 2015 to 32 in 2025, with a sharp increase after 2020 and a notable surge in 2023 (24 articles). Early output was limited (2016–2018: 0–3 per year), followed by steady growth since 2019. Citation impact was higher for earlier studies (264.0 in 2015, 125.3 in 2017) but declined in recent years (7.3 in 2024, 1.0 in 2025), reflecting citation lag. Publications from 2022 also showed relatively high citations (117.1). Overall, research activity has accelerated rapidly. Fig. 2Evolution of the thoracic SMARCA4-UT research enterprise in the life sciences Evolution of the thoracic SMARCA4-UT research enterprise in the life sciences Distribution by country Figure 3 illustrates the global distribution of publications on thoracic SMARCA4-UT according to country scientific production. A full counting approach was applied, in which each publication was assigned to all contributing countries; therefore, the counts represent national participation rather than mutually exclusive publication totals. Based on the updated dataset, research output remains concentrated in a limited number of countries. China was the most frequent contributor, with 38 publications, accounting for 28.8% of the total country-level contributions. Japan ranked second with 31 publications, accounting for 23.5%, followed by the United States with 23 publications, accounting for 17.4%. France also showed notable activity, contributing 10 publications. Other countries contributed fewer studies, including India with 5 publications, Italy with 4 publications, and England with 3 publications. Austria, South Korea, Canada, and Australia each contributed 2 publications. Germany, Singapore, Tunisia, Turkiye, Morocco, Switzerland, South Africa, Spain, Belgium, and Scotland each contributed 1 publication. Overall, the geographical distribution suggests that research on thoracic SMARCA4-UT is primarily driven by countries in East Asia, North America, and Western Europe, while contributions from other regions remain relatively limited. Fig. 3Country distribution of studies on thoracic SMARCA4-UT research Country distribution of studies on thoracic SMARCA4-UT research Distribution by institutions Table 1 presents the top 10 most productive institutions in thoracic SMARCA4-UT research. Memorial Sloan Kettering Cancer Center ranked first with 7 publications, followed by Institut National de la Santé et de la Recherche Médicale (Inserm) with 6 publications and the National Cancer Center of Japan with 5 publications. Several institutions, including Mayo Clinic, All India Institute of Medical Sciences (AIIMS) New Delhi, and Army Medical University, each contributed 4 publications, while the remaining institutions produced 3 publications each. Overall, the results indicate that research output is concentrated in a limited number of leading academic and oncology centers. Table 1Top 10 Institutions of publications in thoracic SMARCA4-UT fromInstitutionPublicationsCentralityMemorial Sloan Kettering Cancer Center70.11Institut National de la Sante et de la Recherche Medicale (Inserm)60.01National Cancer Center - Japan50All India Institute of Medical Sciences (AIIMS) New Delhi40.02Army Medical University40Mayo Clinic40.12Centre Leon Berard30Communaute Universite Grenoble Alpes30.19Institut Bergonie30Ohio State University30.02 Table 1Top 10 Institutions of publications in thoracic SMARCA4-UT fromInstitutionPublicationsCentralityMemorial Sloan Kettering Cancer Center70.11Institut National de la Sante et de la Recherche Medicale (Inserm)60.01National Cancer Center - Japan50All India Institute of Medical Sciences (AIIMS) New Delhi40.02Army Medical University40Mayo Clinic40.12Centre Leon Berard30Communaute Universite Grenoble Alpes30.19Institut Bergonie30Ohio State University30.02 Top 10 Institutions of publications in thoracic SMARCA4-UT from From the perspective of network structure (Fig. 4), notable differences were observed between publication output and collaborative influence. Although some institutions exhibited high productivity, their centrality values were relatively low, suggesting limited roles in bridging different research groups. In contrast, Communauté Université Grenoble Alpes (centrality = 0.19) and Mayo Clinic (centrality = 0.12) showed higher betweenness centrality, indicating their important roles as key connectors within the collaboration network. Memorial Sloan Kettering Cancer Center also demonstrated moderate centrality (0.11), reflecting both strong productivity and a certain level of collaborative influence.The collaboration network reveals several clustered structures, primarily centered around major institutions such as Memorial Sloan Kettering Cancer Center, Inserm, and AIIMS New Delhi. These clusters indicate the presence of relatively stable collaborative groups, while inter-cluster connections remain comparatively limited. Overall, the findings suggest that although thoracic SMARCA4-UT research is driven by a group of core institutions, the global collaboration network is still fragmented, with key bridging institutions playing a crucial role in facilitating knowledge exchange across research groups. Fig. 4The collaborative relationships among leading institutions over the period 2015–2025. Colors progress from black (2015) through intermediate hues to reddish-brown (2025), while the links between nodes indicate the relationships between these institutions The collaborative relationships among leading institutions over the period 2015–2025. Colors progress from black (2015) through intermediate hues to reddish-brown (2025), while the links between nodes indicate the relationships between these institutions Distribution by author Figure 5 illustrates the most productive authors and the temporal distribution of their publications in thoracic SMARCA4-UT research. As shown in Fig. 5A, Rekhtman N is the most prolific contributor, with 6 publications. Jain D, Le Loarer F, and Yoshida A follow, each with 4 publications. A group of authors—including Hasegawa T, Hu ZH, Inoue T, Kuhara H, Kumagai T, and Kunimasa K—have each contributed 3 publications, indicating a relatively concentrated yet collaborative core of active researchers in this field. Figure 5B further depicts the evolution of author productivity over time. The earliest contributions in this dataset appear in 2015, followed by additional publications in 2017. Research activity increased notably from 2019 onward, with a growing number of authors contributing and a more continuous publication pattern observed through 2020–2024. Notably, several publications around 2021–2022 exhibit relatively high citation impact, suggesting increasing academic attention and the ongoing expansion of research in thoracic SMARCA4-UT. Fig. 5Leading contributors and temporal publication patterns in thoracic SMARCA4-UT research Leading contributors and temporal publication patterns in thoracic SMARCA4-UT research Distribution by title word over time Figure 6 illustrates the temporal evolution of research themes in thoracic SMARCA4-UT. Early studies (2015–2017) centered on disease definition and genetic mechanisms, focusing on lung cancer, SWI/SNF complex inactivation, and SMARCA4-deficient carcinoma. From 2018 to 2020, research expanded to pathological classification and epigenetic features, such as EZH2 and BRG1/BRM deficiency. Since 2021, the field has shifted toward molecular function and therapeutic exploration, with keywords including ATPase domain, efficacy, pharmacological approaches, and chromatin remodeling complex emerging. Clinicopathological studies and literature reviews have further advanced systematic understanding of this disease. Overall, SMARCA4-UT research has progressed from genetic and pathological characterization to mechanistic and therapeutic investigations. Fig. 6Title word distribution of studies over time on thoracic SMARCA4-UT research Title word distribution of studies over time on thoracic SMARCA4-UT research Distribution by keyword over time Figure 7 presents the top 25 keywords with the strongest citation bursts, outlining the temporal evolution of research hotspots in thoracic SMARCA4-UT from 2015 to 2025. Citation bursts reflect periods during which specific topics received heightened scholarly attention, thereby highlighting emerging trends and shifting research priorities. In the early stage (2015–2018), burst keywords such as “epithelioid sarcoma” (strength = 2.22), “hypercalcemic type” (1.06), and “rhabdoid cells” (1.24) dominated, indicating that initial studies focused on clinicopathological characterization and histological features of SMARCA4-related tumors. The presence of “small cell carcinoma” and early mentions of “SMARCA4-deficient thoracic sarcoma” (burst beginning in 2017, strength = 2.91) further reflects efforts to define and differentiate this rare entity. During the intermediate phase (2018–2021), research attention shifted toward molecular mechanisms and functional alterations. Keywords such as “BAF complex,” “SWI/SNF complex,” “inactivation,” “inhibition,” and “BRG1” exhibited notable bursts, highlighting increasing interest in chromatin remodeling and gene inactivation pathways. Concurrently, more general pathological terms such as “cell carcinoma,” “deficiency,” and “thoracic sarcoma” (strength = 3.13) gained prominence, suggesting ongoing refinement of disease classification and diagnostic criteria. In the most recent period (2021–2025), emerging bursts indicate a transition toward therapeutic exploration and updated disease concepts. Keywords including “immunotherapy” (1.18), “adenocarcinoma” (1.51), and “expression” (0.53) reflect expanding interest in treatment strategies and molecular profiling. Notably, terms such as “SMARCA4-deficient undifferentiated tumor” (2.85), “undifferentiated tumor” (1.41), “thoracic SMARCA4-deficient undifferentiated tumor” (1.41), and “sarcoma” (2.56) show strong and ongoing bursts through 2025, indicating a recent shift toward reclassification and consensus on disease nomenclature. Additionally, the late emergence of “EZH2” suggests growing attention to potential targeted therapies. Overall, the burst analysis reveals a clear progression from early histopathological recognition to mechanistic insights and, more recently, to therapeutic strategies and refined disease classification, underscoring the dynamic and evolving nature of thoracic SMARCA4-UT research over the past decade. Fig. 7Keyword distribution of studies over time on thoracic SMARCA4-UT research Keyword distribution of studies over time on thoracic SMARCA4-UT research Countries’ collaboration Figure 8 depicts the international collaboration network for thoracic SMARCA4-UT research, which is concentrated in North America, East Asia, and Europe. China and the United States are the leading contributors, followed by Japan and France. The United States maintains the strongest bilateral ties with France, while cross-regional cooperation remains limited, forming a sparse network. Overall, research is dominated by a small number of core countries with uneven collaboration, calling for strengthened global cooperation. Fig. 8Countries’ collaboration world map Countries’ collaboration world map Strategic theme mapping: density-centrality analysis Figure 9 presents the strategic thematic map of thoracic SMARCA4-UT research, which characterizes the conceptual structure of the field by integrating thematic centrality (x-axis, representing relevance) and density (y-axis, representing development). Themes are distributed across four quadrants that reflect their relative importance and maturity within the research domain. The quadrant boundaries are defined using the median values of centrality and density across all identified themes, as commonly implemented in bibliometrix-based analyses. The quadrant boundaries were defined using the median values of Callon’s centrality (5.385) and density (72.872), calculated from the thematic clustering results.Thus, themes located to the right of the vertical dashed line exhibit above-median centrality (high relevance), while those above the horizontal dashed line show above-median density (high development). In the upper-right quadrant (motor themes), well-developed and highly relevant topics dominate the field. Notably, the cluster centered on “BRG1,” “SWI/SNF complex,” and “expression” is positioned in this region, indicating that molecular mechanisms related to chromatin remodeling represent a core and mature driving force in thoracic SMARCA4-UT research. The upper-left quadrant (niche themes) includes highly developed but less central topics, such as “lung,” “thoracic,” and “cancer,” as well as themes related to “chromatin-remodeling complex,” “epigenetics,” and “identification.” These topics are internally cohesive but relatively specialized, with limited connectivity to the broader research network. In the lower-right quadrant (basic themes), clusters including “SMARCA4,” “sarcoma,” and “carcinoma,” along with “immunotherapy,” “lung cancer,” and “chemotherapy,” display high centrality but relatively low density. This suggests that these themes are fundamental and widely connected across the field but remain underdeveloped, representing essential yet still evolving research directions. The lower-left quadrant (emerging or declining themes) contains topics such as “SMARCA4-deficient thoracic sarcoma,” “SWI,” and “BRM,” which exhibit both low centrality and density. These themes may represent either emerging areas of investigation or topics that are gradually losing prominence. Overall, the thematic structure indicates that thoracic SMARCA4-UT research is driven primarily by molecular mechanisms of the SWI/SNF complex, supported by core pathological entities such as SMARCA4-related sarcomas and carcinomas, while therapeutic strategies and specific disease classifications are still in the process of development and consolidation. Fig. 9Thematic evolution and research landscape of thoracic SMARCA4-UT Thematic evolution and research landscape of thoracic SMARCA4-UT Academic and journal development status This journal dual-map (Fig. 10) overlay reveals that SMARCA4-UT research is mainly published in journals related to clinical medicine and molecular biology, whereas the cited literature is largely concentrated in molecular biology and genetics domains. The dominant citation pathways illustrate a unidirectional knowledge flow from basic molecular research to clinical practice, underscoring the pivotal role of genetic and mechanistic studies in shaping this field. This pattern reflects a highly translational research paradigm, wherein insights into chromatin remodeling and SMARCA4 alterations are increasingly integrated into clinical investigation and therapeutic exploration. Fig. 10Interdisciplinary knowledge mapping of thoracic SMARCA4-UT research Interdisciplinary knowledge mapping of thoracic SMARCA4-UT research The top 10 most cited articles Table 2 summarizes the ten most cited SMARCA4-UT-specific publications. The citation counts of these articles ranged from 45 to 307, with a clear predominance of original research articles (7/10), complemented by two reviews and one editorial material. The most highly cited study was published in Nature Genetics in 2015 (307 citations), which first defined SMARCA4 inactivation as a distinct category of undifferentiated thoracic malignancies. Subsequent highly cited works were mainly published between 2017 and 2020 in leading pathology and thoracic oncology journals, including Modern Pathology, Journal of Thoracic Oncology, and American Journal of Surgical Pathology. These studies primarily focused on clinicopathological characterization, diagnostic criteria, and disease classification. More recent publications (2021–2022) have shifted toward therapeutic exploration and tumor microenvironment analysis, particularly immune checkpoint inhibitor efficacy, reflecting an evolving research focus from disease definition to clinical management. Table 3 presents the ten most cited publications broadly related to SWI/SNF complex biology or general thoracic oncology. These articles demonstrated substantially higher citation counts overall (ranging from 20 to 1,178), with the 2022 WHO classification of lung tumors being the most cited (1,178 citations), far exceeding all other publications. Unlike the SMARCA4-UT-specific literature, this group includes a higher proportion of reviews and foundational studies addressing chromatin remodeling mechanisms, targeted therapies, and general lung tumor classification. Journals such as Journal of Thoracic Oncology, Cancer Research, and Molecular Cancer Therapeutics were prominent in this category. These studies provide essential conceptual and methodological frameworks but are not specifically focused on SMARCA4-UT. Overall, the comparison between Tables 2 and 3 highlights a marked difference in citation patterns: while SMARCA4-UT-specific studies contribute directly to disease characterization and clinical research, broadly related literature achieves higher citation counts due to its wider disciplinary relevance. This distinction underscores the necessity of stratified analysis when interpreting citation-based impact in this field. Table 2The ten top-cited SMARCA4-UT-specific publicationsTimes citedPublication yearJournal*Document typeSMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas [58]3072015Nature GeneticsArticleSMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas [8]2562020Journal of Thoracic OncologyArticleClinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities [59]1792017Modern PathologyArticleSMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses [60]1622019American Journal of Surgical PathologyArticleSMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior [6]1592017Modern PathologyArticleExceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report [31]942019Thoracic CancerEditorial MaterialRecent updates in thoracic SMARCA4-deficient undifferentiated tumor [22]792021Seminars in Diagnostic PathologyReviewImaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients [21]572019European RadiologyArticleImmune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors [28]552022OncologistArticleEfficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor [61]452022Clinical Lung CancerReview* The journals’ acronym is derived from Web of Science Table 2The ten top-cited SMARCA4-UT-specific publicationsTimes citedPublication yearJournal*Document typeSMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas [58]3072015Nature GeneticsArticleSMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas [8]2562020Journal of Thoracic OncologyArticleClinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities [59]1792017Modern PathologyArticleSMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses [60]1622019American Journal of Surgical PathologyArticleSMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior [6]1592017Modern PathologyArticleExceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report [31]942019Thoracic CancerEditorial MaterialRecent updates in thoracic SMARCA4-deficient undifferentiated tumor [22]792021Seminars in Diagnostic PathologyReviewImaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients [21]572019European RadiologyArticleImmune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors [28]552022OncologistArticleEfficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor [61]452022Clinical Lung CancerReview* The journals’ acronym is derived from Web of Science The ten top-cited SMARCA4-UT-specific publications * The journals’ acronym is derived from Web of Science Table 3The ten top-cited broad SWI/SNF or thoracic oncology literatureTimes citedPublication yearJournal*Document typeThe 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 [12]11782022Journal of Thoracic OncologyArticleThe SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies [62]2212015Cancer ResearcArticlelung neuroendocrine neoplasms: recent progress and persistent challenges [63]1542022Modern PathologyArticleSMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy [64]1472021Molecular Cancer TherapeuticsReviewTazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C [87]802023JNCI-Journal of the National Cancer InstituteArticleUpdate on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors [48]562021Virchows ArchivReviewSMARCA family of genes [65]532020Journal of Clinical PathologyArticleTargeting SWI/SNF complexes in cancer: pharmacological approaches and implications [66]262024EpigenomesReviewSWI/SNF-deficient thoraco-pulmonary neoplasms [67]252021Seminars in Diagnostic PathologyReviewSMARCA4 and SMARCA2 co-deficiency: an uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling [68]202024Cancer LettersArticle* The journals’ acronym is derived from Web of Science Table 3The ten top-cited broad SWI/SNF or thoracic oncology literatureTimes citedPublication yearJournal*Document typeThe 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 [12]11782022Journal of Thoracic OncologyArticleThe SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies [62]2212015Cancer ResearcArticlelung neuroendocrine neoplasms: recent progress and persistent challenges [63]1542022Modern PathologyArticleSMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy [64]1472021Molecular Cancer TherapeuticsReviewTazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C [87]802023JNCI-Journal of the National Cancer InstituteArticleUpdate on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors [48]562021Virchows ArchivReviewSMARCA family of genes [65]532020Journal of Clinical PathologyArticleTargeting SWI/SNF complexes in cancer: pharmacological approaches and implications [66]262024EpigenomesReviewSWI/SNF-deficient thoraco-pulmonary neoplasms [67]252021Seminars in Diagnostic PathologyReviewSMARCA4 and SMARCA2 co-deficiency: an uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling [68]202024Cancer LettersArticle* The journals’ acronym is derived from Web of Science The ten top-cited broad SWI/SNF or thoracic oncology literature * The journals’ acronym is derived from Web of Science Discussion Major findings and research landscape This study provides the first comprehensive bibliometric overview of thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT). Bibliometric evidence clearly places SMARCA4-UT research in the growth phase of its lifecycle, supported by a 31.95% annual growth rate, exponential publication growth since 2020, sustained keyword bursts, and an early-stage clinical research landscape. Two core contradictions define the field: mechanistic research is relatively mature, yet clinical translation lags substantially; China leads in publication volume, but exhibits weak international collaboration and limited high-impact output. Consistent with this imbalance, mechanistic studies are well-established while clinical applications remain nascent, reflecting a rapidly expanding but immature field with rising academic influence, as indicated by an average of 32.25 citations per article. Geographically, research is dominated by China (28.8%) and Japan (23.5%), consistent with the concentrated expertise typical of rare diseases. The dual-core collaboration network led by China and the United States, with an international co-authorship rate of only 7.58%, further highlights the urgent need for global cooperation to overcome limitations in case availability and data sharing. At the conceptual level, the field is characterized by a stable mechanistic foundation centered on the SWI/SNF complex and BRG1, alongside comparatively underdeveloped clinical and therapeutic domains. This imbalance suggests that, despite substantial progress in understanding the molecular basis of SMARCA4 deficiency, translation into clinical application remains limited. Collectively, these findings position SMARCA4-UT research as an emerging but still maturing field, with a clear need to bridge mechanistic insights and clinical practice. Evolution of research topic The temporal evolution of SMARCA4-UT research reflects a progressive shift from basic mechanisms to clinical application. Early studies focused primarily on chromatin remodeling [58], SWI/SNF complex dysfunction, and tumor suppressor mechanisms [6, 7]. establishing the biological foundation of the disease. Between 2018 and 2020, research emphasis moved toward clinicopathological characterization and diagnostic refinement, particularly in differentiating SMARCA4-UT from morphologically similar entities [8]. Since 2021, the introduction of standardized terminology, especially following the WHO classification, has marked a transition toward diagnostic consolidation and improved disease recognition [12]. This shift underscores the critical role of classification systems in shaping research direction in rare malignancies. From a thematic perspective, mechanistic research—represented by the SWI/SNF complex and BRG1—remains central, supporting ongoing efforts to identify therapeutic vulnerabilities. Meanwhile, clinically oriented topics, including SMARCA4-related tumors and immunotherapy, are gaining prominence but remain relatively underdeveloped. Basic themes such as “SMARCA4,” “sarcoma,” and “carcinoma,” together with therapeutic strategies including immunotherapy [61, 69–72], and chemoimmunotherapy [26, 69, 70, 73–75] reflect increasing clinical awareness but also highlight unresolved questions regarding treatment response, resistance mechanisms, and tumor microenvironment interactions. In addition, the dynamic behavior of emerging and declining keywords—such as “SMARCA4-deficient thoracic sarcoma,” “SWI,” and “BRM”—suggests ongoing refinement of disease classification and research priorities. Overall, these patterns indicate a gradual transition from mechanistic exploration to translational research. However, a substantial gap remains in converting molecular insights into effective and standardized therapeutic strategies. Therapeutic landscape Thoracic SMARCA4-UT is a rare, highly aggressive malignancy with no standardized treatment and poor prognosis. Conventional chemotherapy and radiotherapy offer limited efficacy and poor disease control, representing an unmet clinical need [11, 23, 73, 76]. Immune checkpoint inhibitor (ICI) monotherapy shows inconsistent activity. Case reports have demonstrated rapid responses to agents such as tislelizumab [71], pembrolizumab [31, 77] or nivolumab [29, 78]. In addition, combination immunotherapy (e.g., ipilimumab plus nivolumab or pembrolizumab regimens) has also shown encouraging activity in individual cases [30, 72]. A retrospective study involving 18 patients reported an objective response rate (ORR) of 42%, with improved efficacy observed in first-line ICI treatment and in patients with sarcomatoid features [61]. However, the efficacy of ICI monotherapy remains inconsistent: PD-L1 and TMB are unreliable predictors, and median progression-free survival is limited (2.4 months), with frequent early progression [61]. By contrast, immunochemotherapy has emerged as the preferred first-line backbone. Retrospective data demonstrate superior PFS compared with chemotherapy alone (26.8 vs. 2.73 months), with consistent benefits across molecular subgroups [25, 69, 70, 74, 75, 79–81]. Combination strategies incorporating immune checkpoint inhibitors (ICIs) with anti-angiogenic agents or radiotherapy have demonstrated potential synergistic antitumor effects in selected patient populations, including those with immunocompromised status or intermediate PD-L1 expression [82]. in a retrospective cohort, this regimen yielded significantly longer OS (not reached vs. 21.67 months; p = 0.02) than chemoimmunotherapy, chemotherapy plus anti-angiogenics, or chemotherapy alone [83], Triple therapy combining immunotherapy, chemotherapy, and anti-angiogenics has shown encouraging activity even in PD-L1-negative patients, supporting broader applicability [84]. Similarly, in three patients with SMARCA4-deficient thoracic sarcoma treated with the first-line ABCP regimen (atezolizumab, bevacizumab, paclitaxel, and carboplatin), all achieved partial response, with a median PFS of over 6 months and one patient maintaining remission for more than one year [25]. In addition to combination immunotherapy strategies, targeted therapy has emerged as a promising research direction for SMARCA4-deficient thoracic tumors, particularly in patients with specific molecular alterations or those refractory to conventional treatment. Current approaches mainly focus on targeting SWI/SNF-related vulnerabilities, including SMARCA4/2 inhibition, small molecules targeting SWI/SNF bromodomains, and proteolysis-targeting chimeras (PROTACs) [66], as well as BET, HDAC, and CDK4/6 inhibitors [64, 85]. Although ALK fusions are generally considered rare in SMARCA4-deficient undifferentiated tumors (SMARCA4-UT), a case report [86] described a nonsmoking female patient harboring concurrent ALK rearrangement and SMARCA4 deficiency who achieved marked tumor regression with the ALK inhibitor alectinib, highlighting the importance of comprehensive molecular profiling. Epigenetic therapies, particularly EZH2 inhibition, have also shown potential [87] Although objective responses were not achieved, prolonged stable disease was observed in 25% of refractory pediatric tumors, including one case with SMARCA4 loss. In addition, emerging evidence from broader oncological research suggests that tumor-associated secretory factors and immune microenvironment regulators, such as ZG16B [71], may represent novel therapeutic targets. Nevertheless, several challenges remain. Most SWI/SNF-targeted strategies are still in the preclinical stage, actionable alterations such as ALK fusions are rare, and EZH2 inhibitors have shown limited efficacy in inducing objective responses. In summary, immunochemotherapy is the current first-line standard, while anti-angiogenic and triple combinations provide synergistic benefits. Targeted and epigenetic approaches remain exploratory. Future efforts should focus on optimizing combination regimens, identifying predictive biomarkers, and validating novel agents in prospective trials. Future directions Future research on SMARCA4-UT should prioritize three core directions, which are expected to dominate the field over the next 3–5 years. First, large-scale, multi-institutional prospective and real-world studies are essential to validate current combination regimens and establish standardized treatment guidelines. Second, dissecting immune resistance mechanisms and identifying reliable predictive biomarkers—including TMB, STK11/KEAP1 co-mutations, and immune microenvironment profiling—will be critical to optimize patient selection and overcome immunotherapy failure. Third, exploring SWI/SNF-targeted agents (e.g., EZH2, BET, or CDK4/6 inhibitors) combined with immunotherapy represents a promising strategy to enhance antitumor efficacy and achieve personalized treatment. These focused efforts will help bridge the gap between mechanistic insights and clinical practice, ultimately improving long-term outcomes for patients with this aggressive disease. Limitations This study has several limitations. First, although both WoSCC and Scopus were searched to minimize database-selection bias, relevant publications indexed in other databases (e.g., PubMed and Embase) may have been missed. Second, the restriction to English-language publications may have excluded pertinent studies published in other languages, particularly from China and Japan, which are major contributors to SMARCA4-UT research. Third, due to the rapidly evolving nature of the field, recently published high-impact studies may be underrepresented because of citation time lag. In addition, the rarity and heterogeneity of SMARCA4-UT may contribute to fragmented research outputs and limited statistical robustness in certain clusters. A key limitation of bibliometric analysis is citation inflation from broadly cited, non-specific publications. In this study, highly cited articles (e.g., WHO classifications and SWI/SNF-related studies) may inflate aggregate metrics due to their cross-disciplinary relevance rather than specific focus on SMARCA4-UT. To address this, publications were stratified into disease-specific and broadly related categories, allowing clearer delineation of the field’s core knowledge base. Conclusion This study provides a comprehensive bibliometric overview of thoracic SMARCA4-UT, highlighting a rapidly expanding yet still evolving research field. While mechanistic insights into SWI/SNF dysfunction are well developed, clinical translation—particularly in diagnosis and treatment—remains limited. Immunotherapy-based strategies show promise but lack consistent efficacy and reliable biomarkers. Overall, advancing translational research, fostering global collaboration, and developing personalized therapeutic approaches will be critical to improving outcomes in this aggressive malignancy. Future research should strengthen international collaboration, prioritize mechanism-driven clinical trials, and establish standardized diagnostic and therapeutic guidelines for SMARCA4-UT. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1